Tacrolimus
- Generic Name
- Tacrolimus
- Brand Names
- Advagraf, Astagraf, Envarsus, Modigraf, Prograf, Protopic, Tacforius
- Drug Type
- Small Molecule
- Chemical Formula
- C44H69NO12
- CAS Number
- 104987-11-3
- Unique Ingredient Identifier
- Y5L2157C4J
- Background
Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condi...
- Indication
Immediate-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants. Extended-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric ...
- Associated Conditions
- Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Oral Lichen Planus, Psoriasis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Atopic Dermatitis, Vitiligo, Moderate Atopic dermatitis
- Associated Therapies
- -
Evaluation of Cyclosporine Microemulsion and Tacrolimus on the Rate of New Onset Diabetes Mellitus in Kidney Transplantation Recipients
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 693
- Registration Number
- NCT00171496
Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
- Conditions
- Interventions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 312
- Registration Number
- NCT00163657
- Locations
- 🇺🇸
Baylor Regional Transplant Institute - Baylor University Medical Center, Dallas, Texas, United States
Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 111
- Registration Number
- NCT00157014
Reduction of Tacrolimus Dose in Association With Mycophenolate Mofetil After Liver Transplantation
- Conditions
- Interventions
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2012-07-04
- Lead Sponsor
- Rennes University Hospital
- Target Recruit Count
- 195
- Registration Number
- NCT00151632
- Locations
- 🇫🇷
Service de Chirurgie Digestive - Hôpital de la Côte de Nacre, Caen, France
🇫🇷Service d'Hépatogastroentérologie - Hôpital Beaujon, Clichy, France
🇫🇷Service d'Hépatogastroentérologie - Hôpital Henri Mondor, Créteil, France
Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2010-06-09
- Lead Sponsor
- Technische Universität Dresden
- Registration Number
- NCT00148746
- Locations
- 🇩🇪
Department of Dermatology, TU Dresden, Dresden, Germany
Th1, Th2 and Monokine Responses as Risk Factors of Renal Transplant Rejection
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2007-05-10
- Lead Sponsor
- University of Giessen
- Target Recruit Count
- 84
- Registration Number
- NCT00150891
- Locations
- 🇩🇪
Department of Internal Medicine, University of Giessen, Giessen, Germany
Cyclosporine A C-2h Monitoring Versus Tacrolimus C-0h Monitoring in de Novo Liver Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 171
- Registration Number
- NCT00149994
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Effectiveness and Safety of Campath in Combination With Tacrolimus Monotherapy to Prevent Kidney Graft Rejection
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2012-06-19
- Lead Sponsor
- Dr. Claudia Bösmüller
- Target Recruit Count
- 197
- Registration Number
- NCT00147381
- Locations
- 🇦🇹
University Hospital Innsbruck, Innsbruck, Tyrol, Austria
Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2012-03-08
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 105
- Registration Number
- NCT00146614
- Locations
- 🇺🇸
Beth Isreal Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2012-01-26
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 55
- Registration Number
- NCT00144703
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.